Renal Cell Carcinoma

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet A Bilen, Mark Stein, Jeffrey Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael Hurwitz, David J Peace, David Einstein, Paul J Catalano, Hans Hammers, Meredith M Regan

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e008293; DOI: 10.1136/jitc-2023-008293
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
Jihua Tian, Jing Luo, Xing Zeng, Chunjin Ke, Yanan Wang, Zhenghao Liu, Le Li, Yangjun Zhang, Zhiquan Hu, Chunguang Yang

Journal for ImmunoTherapy of Cancer Feb 2024, 12 (2) e008226; DOI: 10.1136/jitc-2023-008226
Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis
Jimmy S Patel, Yena Woo, Amber Draper, Caroline S Jansen, Jennifer W Carlisle, Pasquale F Innominato, Francis A Lévi, Layla Dhabaan, Viraj A Master, Mehmet A Bilen, Mohammad K Khan, Michael C Lowe, Haydn Kissick, Zachary S Buchwald, David C Qian

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (3) e008011; DOI: 10.1136/jitc-2023-008011
NKG2A⁺CD8⁺ T cells infiltration determines immunosuppressive contexture and inferior response to immunotherapy in clear cell renal cell carcinoma
Youqi Qiu, Li Liu, Wenbin Jiang, Ziyang Xu, Jiahao Wang, Siyuan Dai, Jianming Guo, Jiejie Xu

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e008368; DOI: 10.1136/jitc-2023-008368
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma
Manon de Vries-Brilland, Nathalie Rioux-Leclercq, Maxime Meylan, Jonathan Dauvé, Christophe Passot, Elena Spirina-Menand, Ronan Flippot, Gaëlle Fromont, Gwenaelle Gravis, Lionnel Geoffrois, Christine Chevreau, Fréderic Rolland, Ellen Blanc, Félix Lefort, Alain Ravaud, Marine Gross-Goupil, Bernard Escudier, Sylvie Negrier, Laurence Albiges

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (11) e006885; DOI: 10.1136/jitc-2023-006885
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
David A Schoenfeld, Myrto Moutafi, Sandra Martinez, Dijana Djureinovic, Ross D Merkin, Adebowale Adeniran, David A Braun, Sabina Signoretti, Toni K Choueiri, Fabio Parisi, Michael Hurwitz, David L Rimm, Wei Wei, Lucia Jilaveanu, Harriet M Kluger

Journal for ImmunoTherapy of Cancer Aug 2023, 11 (8) e007240; DOI: 10.1136/jitc-2023-007240
Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Wenhao Xu, Jiahe Lu, Wang-Rui Liu, Aihetaimujiang Anwaier, Yuhao Wu, Xi Tian, Jia-Qi Su, Yuan-Yuan Qu, Jianfeng Yang, Hailiang Zhang, Dingwei Ye

Journal for ImmunoTherapy of Cancer Dec 2023, 11 (12) e006667; DOI: 10.1136/jitc-2023-006667
KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response
Casey R Ager, Mingxuan Zhang, Matthew Chaimowitz, Shruti Bansal, Somnath Tagore, Aleksandar Obradovic, Collin Jugler, Meri Rogava, Johannes C Melms, Patrick McCann, Catherine Spina, Charles G Drake, Matthew C Dallos, Benjamin Izar

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e006782; DOI: 10.1136/jitc-2023-006782
Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy
Craig Labbate, Ken Hatogai, Ryan Werntz, Walter M. Stadler, Gary D. Steinberg, Scott Eggener, Randy F. Sweis

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 66; DOI: 10.1186/s40425-019-0546-8
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, Diana Giannarelli, Andrea De Giglio, Roberto Sabbatini, Sebastiano Buti, Sabrina Rossetti, Francesco Cognetti, Francesca Rastelli, Alberto Sobrero, Daniele Turci, Cora N. Sternberg, Camillo Porta, Federico Cappuzzo, Giampaolo Tortora, Davide Tassinari, Stefano Panni, Antonio Pazzola, Gianmarco Surico, Alessandra Raimondi, Ugo De Giorgi, Giuseppe Procopio, on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 99; DOI: 10.1186/s40425-019-0579-z

Main menu

Renal Cell Carcinoma

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Renal Cell Carcinoma

Pages